Tuberculosis cutis orificialis
Tuberculosis Cutis Orificialis
| Tuberculosis cutis orificialis | |
|---|---|
| ICD-10 | |
| ICD-9 | |
| DiseasesDB | |
| MedlinePlus | |
| eMedicine | |
| MeSH ID | |
Tuberculosis cutis orificialis is a rare form of cutaneous tuberculosis that occurs when Mycobacterium tuberculosis infects the skin at the mucocutaneous junctions, such as the mouth, anus, or genitals. This condition is typically seen in individuals with advanced pulmonary tuberculosis and is considered a sign of disseminated disease.
Clinical Presentation[edit]
Patients with tuberculosis cutis orificialis present with ulcerative lesions at the mucocutaneous junctions. These lesions are often painful and may bleed. The condition is more common in adults and is associated with a high bacterial load in the body.
Pathophysiology[edit]
The disease occurs when Mycobacterium tuberculosis spreads from an internal focus, such as the lungs, to the skin. The bacteria reach the skin through the bloodstream or lymphatic system and establish infection at sites where the skin meets mucous membranes.
Diagnosis[edit]
Diagnosis of tuberculosis cutis orificialis involves a combination of clinical examination and laboratory tests. A biopsy of the lesion can reveal granulomatous inflammation, and culture or polymerase chain reaction (PCR) can confirm the presence of Mycobacterium tuberculosis.
Treatment[edit]
The primary treatment for tuberculosis cutis orificialis is antitubercular therapy, which includes a combination of antibiotics such as isoniazid, rifampicin, ethambutol, and pyrazinamide. Treatment duration is typically 6 to 12 months, depending on the severity and response to therapy.
Prognosis[edit]
The prognosis for tuberculosis cutis orificialis depends on the control of the underlying tuberculosis infection. With appropriate treatment, the skin lesions can heal, although scarring may occur. However, if the systemic disease is not controlled, the prognosis is poor.
See Also[edit]
References[edit]
External Links[edit]
- [World Health Organization - Tuberculosis](https://www.who.int/health-topics/tuberculosis)
- [Centers for Disease Control and Prevention - Tuberculosis](https://www.cdc.gov/tb/)
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian